Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eiger BioPharmaceuticals, Inc. operates as a biopharmaceutical company, which focuses on the development of innovative therapies for rare metabolic diseases. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Eiger BioPharma (EIGR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Eiger BioPharma (EIGR) Upgraded to Strong Buy: What Does It Mean for the Stock?

Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Eiger BioPharmaceuticals (EIGR) Stock Might be a Great Pick

PALO ALTO, Calif., May 29, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the...

Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020

PALO ALTO, Calif., May 26, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the...

Eiger to Present at Jefferies Virtual Healthcare Conference 2020

PALO ALTO, Calif., May 19, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the New...

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies

Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now?

Eiger BioPharmaceuticals: Promising COVID-19 Effort With Peginterferon Lambda Just Entering Clinical Trials

As of late, it has definitely been a great time to be an investor Eiger BioPharmaceuticals

Will Eiger BioPharmaceuticals Continue to Surge Higher?

Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.

Eiger Completes NDA Submission of Progeria Drug Lonafarnib

Eiger BioPharma (EIGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Eiger BioPharma (EIGR) a New Buy Stock

EIGR has an NDA upcoming for an ultrarare disease, but another phase 3 trial ongoing for the first antiviral against the hepatitis D virus.

Eiger BioPharmaceuticals: NDA For HGPS, Phase 3 Ongoing In HDV, Solid Potential

Biohaven Pharmaceutical Hld

Calithera Biosciences

Rockwell Medical

Tuesday was a breakout day for a few biotech companies, and that was the case even before news broke that the U.S. and China would be meeting at the G20 meeting in Japan.

Tuesday’s Top BioPharma Movers Deviating from the Market

News for Eiger BioPharmaceuticals Stock (EIGR)